Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 10, 2026CancersOpen Access

Programmed Death-Ligand 1 Expression in Triple-Negative Breast Cancer: Insights from a Mexican Cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

CVCynthia Villarreal‐GarzaCLCésar Octavio Lara-TorresJHJ. E. Hernandez-Hernandez

Discussion

Loading...

Member takes

Overview

Retrospective study characterizes PD-L1 expression in triple-negative breast cancer, suggesting implications for treatment efficacy in Mexican women.

Key Points

  • This study aims to assess PD-L1 positivity rates in a Mexican cohort of women with triple-negative breast cancer (TNBC).
  • Conducted a retrospective analysis across two cancer centers in Mexico from 2006 to 2021.
  • Evaluated PD-L1 expression using the 22C3 pharmDx assay with CPS ≥1 considered positive.
  • Explored associations between PD-L1 expression and clinicopathological features.
  • Out of 298 TNBC patients, 285 were evaluated, revealing a PD-L1 positivity rate of 29.1%.
  • Among those, 13.3% had a CPS ≥ 10, indicating high PD-L1 expression.
  • PD-L1 positivity correlated with higher histological grades and tumor-infiltrating lymphocytes.

Cite This Study

Villarreal‐Garza et al. (2026) studied this question.

synapsesocial.com/papers/6a508c766eeac72a437a08fdhttps://doi.org/10.3390/cancers18142182
View Full Paper
Ask AI
Bookmark
Share